Oxford BioDynamics PLC EXERCISE OF WARRANTS AND DIRECTOR DEALING (3583Y)

TIDMOBD

RNS Number : 3583Y

Oxford BioDynamics PLC

05 December 2017

OXFORD BIODYNAMICS PLC

EXERCISE OF WARRANTS, DIRECTOR DEALING AND TOTAL VOTING RIGHTS

London, 5 December 2017: Oxford BioDynamics Plc (AIM: OBD) (the "Company") announces that it has received notice from Wentworth Limited ("Wentworth") of the exercise of 689,441 warrants in exchange for the issue of 689,441 ordinary shares of 1 pence each ("Ordinary Shares") (the "New Ordinary Shares"). The warrant exercise was effected at the nominal price of 1 pence per Ordinary Share and, in accordance with the terms of the warrant instrument, Wentworth has simultaneously waived its subscription rights to the balance of 1,032,523 warrant shares previously held.

Warrants over 1,721,964 Ordinary Shares were granted to Wentworth on 30 November 2016 in consideration for Wentworth procuring placees pursuant to the placing which took place on 6 December 2016, and general corporate and strategic advice. David Williams, the Company's Chairman, is the beneficial owner of Wentworth.

Following exercise of these warrants, through his beneficial ownership of Wentworth, David Williams will be interested in a total of 1,322,352 Ordinary Shares of 1 pence each in the Company, representing approximately 1.52% of the Company's issued share.

Application will be made for the New Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, to be admitted to trading on AIM which is expected to occur on or around 12 December 2017.

Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 86,787,669 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 86,787,669. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                      David Williams 
---  ------------------------  ---------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status           Non-Executive Chairman 
---  ------------------------  ---------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                      Oxford BioDynamics Plc 
---  ------------------------  ---------------------------------- 
 b)   LEI                       2138005Y1TK258O5U928 
---  ------------------------  ---------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ------------------------------------------------------------ 
 a)   Description of            Ordinary shares of 1 pence each 
       the financial 
       instrument, type          ISIN: GB00BD5H8572 
       of instrument 
       Identification 
       code 
---  ------------------------  ---------------------------------- 
 b)   Nature of the             Exercise of warrants 
       transaction 
---  ------------------------  ---------------------------------- 
 c)   Price(s) and              1 pence per ordinary share 
       volume(s) 
                                 689,441 ordinary shares 
---  ------------------------  ---------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  ---------------------------------- 
 e)   Date of the transaction   4 December 2017 
---  ------------------------  ---------------------------------- 
 f)   Place of the              London Stock Exchange, AIM (XLON) 
       transaction 
---  ------------------------  ---------------------------------- 
 

For further details, contact:

 
 Oxford BioDynamics 
  Plc                           [phone] 
 Christian Hoyer Millar, 
  CEO 
 Paul Stockdale, CFO 
 
 Stifel Nicolaus Europe 
  Limited                       [phone] 
 Nominated Advisor 
  and Broker 
 David Arch 
 Jonathan Senior 
 Peter Lees 
 Ben Maddison 
 
 Shore Capital                  [phone] 
 Joint Broker 
 Edward Mansfield 
 
 FTI Consulting                 [phone] 
 Financial Public Relations 
  Advisor 
 Julia Phillips 
 Brett Pollard 
 Natalie Garland-Collins 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNEAEALEAXXFAF

(END) Dow Jones Newswires

December 05, 2017 02:01 ET (07:01 GMT)